PL2286794T3 - Zastosowanie kationowych liposomów zawierających paklitaksel - Google Patents
Zastosowanie kationowych liposomów zawierających paklitakselInfo
- Publication number
- PL2286794T3 PL2286794T3 PL10180750.1T PL10180750T PL2286794T3 PL 2286794 T3 PL2286794 T3 PL 2286794T3 PL 10180750 T PL10180750 T PL 10180750T PL 2286794 T3 PL2286794 T3 PL 2286794T3
- Authority
- PL
- Poland
- Prior art keywords
- paclitaxel
- cationic liposomes
- liposomes
- cationic
- Prior art date
Links
- 229930012538 Paclitaxel Natural products 0.000 title 1
- 125000002091 cationic group Chemical group 0.000 title 1
- 239000002502 liposome Substances 0.000 title 1
- 229960001592 paclitaxel Drugs 0.000 title 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Epoxy Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03023539 | 2003-10-15 | ||
| EP04000361 | 2004-01-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2286794T3 true PL2286794T3 (pl) | 2016-10-31 |
Family
ID=34524705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10180750.1T PL2286794T3 (pl) | 2003-10-15 | 2004-10-15 | Zastosowanie kationowych liposomów zawierających paklitaksel |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20080063699A1 (enExample) |
| EP (2) | EP2286794B8 (enExample) |
| JP (2) | JP5645340B2 (enExample) |
| AU (1) | AU2004283464B8 (enExample) |
| CA (1) | CA2542217C (enExample) |
| DK (1) | DK2286794T3 (enExample) |
| ES (1) | ES2574231T3 (enExample) |
| HU (1) | HUE028648T2 (enExample) |
| PL (1) | PL2286794T3 (enExample) |
| PT (1) | PT2286794T (enExample) |
| WO (1) | WO2005039533A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10347710B4 (de) | 2003-10-14 | 2006-03-30 | Johannes-Gutenberg-Universität Mainz | Rekombinante Impfstoffe und deren Verwendung |
| US20050255154A1 (en) | 2004-05-11 | 2005-11-17 | Lena Pereswetoff-Morath | Method and composition for treating rhinitis |
| WO2006089290A1 (en) | 2005-02-18 | 2006-08-24 | Abraxis Bioscience Inc.. | Combinations and modes of administration of therapeutic agents and combination therapy |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| US9233094B2 (en) | 2005-05-04 | 2016-01-12 | Medigene Ag | Method of administering a cationic liposomal preparation |
| BRPI0615032A2 (pt) * | 2005-09-01 | 2011-04-26 | Biolipox Ab | composição farmacêutica, processo para a preparação da mesma, e, uso de uma composição |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| KR100658436B1 (ko) * | 2005-12-09 | 2006-12-27 | 한국화학연구원 | 아데노실코발라민 함유 피부질환 치료용 외용제 조성물 |
| AU2007228984B2 (en) * | 2006-03-22 | 2012-05-03 | Syncore Biotechnology Co., Ltd | Treatment of triple receptor negative breast cancer |
| EP2040674B1 (en) * | 2006-05-18 | 2010-07-07 | MediGene AG | Cationic liposomal preparations for the treatment of rheumatoid arthritis |
| WO2011123393A1 (en) | 2010-03-29 | 2011-10-06 | Abraxis Bioscience, Llc | Methods of enhancing drug delivery and effectiveness of therapeutic agents |
| NZ602385A (en) | 2010-03-29 | 2014-08-29 | Abraxis Bioscience Llc | Methods of treating cancer |
| EP2394640A1 (en) | 2010-05-21 | 2011-12-14 | MediGene AG | Improved liposomal formulations of lipophilic compounds |
| KR20130088116A (ko) | 2010-06-04 | 2013-08-07 | 아브락시스 바이오사이언스, 엘엘씨 | 췌장암의 치료 방법 |
| US20120028335A1 (en) | 2010-07-28 | 2012-02-02 | Life Technologies Corporation | Anti-viral azide-containing compounds |
| US9144575B2 (en) | 2010-07-28 | 2015-09-29 | Life Technologies Corporation | Anti-viral azide containing compounds |
| WO2012075210A2 (en) * | 2010-12-01 | 2012-06-07 | Niiki Pharma Inc. | Method for treating refractory cancer |
| PL3892295T3 (pl) | 2011-05-24 | 2023-07-24 | BioNTech SE | Zindywidualizowane szczepionki przeciwnowotworowe |
| SG11201404361UA (en) | 2012-01-26 | 2014-09-26 | Life Technologies Corp | Methods for increasing the infectivity of viruses |
| WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| EP2925348B1 (en) | 2012-11-28 | 2019-03-06 | BioNTech RNA Pharmaceuticals GmbH | Individualized vaccines for cancer |
| DE102013009744A1 (de) * | 2013-03-26 | 2014-10-02 | Forschungszentrum Jülich GmbH | Fusionsmischung zur lipidhaltigen Membranmodifikation einer beliebigen Lipidmembran, einer Zellmembran, einem Bestandteil einer Zellmembran oder einer von den übrigen Zell- Bestandteilen getrennten Zellmembran in vivo oder in vitro |
| WO2014180490A1 (en) | 2013-05-10 | 2014-11-13 | Biontech Ag | Predicting immunogenicity of t cell epitopes |
| WO2016045732A1 (en) | 2014-09-25 | 2016-03-31 | Biontech Rna Pharmaceuticals Gmbh | Stable formulations of lipids and liposomes |
| WO2016128060A1 (en) | 2015-02-12 | 2016-08-18 | Biontech Ag | Predicting t cell epitopes useful for vaccination |
| JP6921759B2 (ja) | 2015-06-04 | 2021-08-18 | クリティテック・インコーポレイテッド | 捕集装置および使用法 |
| AU2016323770A1 (en) | 2015-09-16 | 2018-03-29 | Dfb Soria, Llc | Delivery of drug nanoparticles and methods of use thereof |
| WO2017059902A1 (en) | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
| SG10201913409VA (en) | 2016-04-04 | 2020-03-30 | Crititech Inc | Methods for solid tumor treatment |
| US20190343763A1 (en) * | 2016-11-11 | 2019-11-14 | Western University Of Health Sciences | Methods of treating upper tract urothelial carcinomas |
| TWI852903B (zh) | 2017-01-05 | 2024-08-21 | 杏國新藥股份有限公司 | 胰臟癌治療 |
| JP2020514359A (ja) | 2017-03-15 | 2020-05-21 | ディーエフビー ソリア リミテッド ライアビリティ カンパニー | タキサンのナノ粒子を用いる皮膚悪性腫瘍処置のための局所療法 |
| SG11201909840TA (en) | 2017-06-09 | 2019-11-28 | Crititech Inc | Treatment of epithelial cysts by intracystic injection of antineoplastic particles |
| WO2018224166A1 (en) | 2017-06-09 | 2018-12-13 | Biontech Rna Pharmaceuticals Gmbh | Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy |
| CN115919815A (zh) | 2017-06-14 | 2023-04-07 | 克里蒂泰克公司 | 治疗肺部疾病的方法 |
| KR20200064112A (ko) | 2017-10-03 | 2020-06-05 | 크리티테크, 인크. | 암의 치료를 위한 면역치료제의 전신 전달과 조합된 항신생물성 입자의 국소 전달 |
| KR20200132963A (ko) | 2018-03-16 | 2020-11-25 | 디에프비 소리아, 엘엘씨 | 탁산의 나노입자를 사용하는 자궁경부 상피내 신생물 (cin) 및 자궁경부 암의 치료를 위한 국소적 요법 |
| KR20250126139A (ko) * | 2023-01-31 | 2025-08-22 | 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 | 종양을 치료하는 파클리탁셀 양이온성 리포솜의 용도 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1254135B (it) | 1992-01-16 | 1995-09-08 | Sigma Tau Ind Farmaceuti | Esteri di acil carnitine con alcooli alifatici a lunga catena e composizioni farmaceutiche che li contengono, ad attivita' antibatterica. |
| DE69329073T2 (de) * | 1992-03-23 | 2001-01-18 | Georgetown University, Washington | In liposomen verkapseltes taxol und verwendungsverfahren |
| DE4430593C2 (de) * | 1994-08-20 | 1999-01-14 | Max Delbrueck Centrum | Verfahren zur Herstellung von Liposomal verkapseltem Taxol |
| US7112338B2 (en) * | 1997-03-12 | 2006-09-26 | The Regents Of The University Of California | Cationic liposome delivery of taxanes to angiogenic blood vessels |
| US5837283A (en) * | 1997-03-12 | 1998-11-17 | The Regents Of The University Of California | Cationic lipid compositions targeting angiogenic endothelial cells |
| US7314637B1 (en) * | 1999-06-29 | 2008-01-01 | Neopharm, Inc. | Method of administering liposomal encapsulated taxane |
| US6146659A (en) * | 1998-07-01 | 2000-11-14 | Neopharm, Inc. | Method of administering liposomal encapsulated taxane |
| HK1046506B (en) * | 1999-09-09 | 2006-08-25 | The Regents Of The University Of California | Cationic liposome delivery of taxanes to angiogenic blood vessels |
| UY27185A1 (es) * | 2001-02-28 | 2002-09-30 | Bristol Myers Squibb Co | Dosificación metronómica de taxanos |
| JP4975964B2 (ja) * | 2002-06-26 | 2012-07-11 | メディゲーネ アクチエンゲゼルシャフト | 脂肪親和性化合物から成る陽イオン性リポソームの製法 |
| WO2004002455A1 (en) * | 2002-06-26 | 2004-01-08 | Medigene Oncology Gmbh | Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system |
-
2004
- 2004-10-15 EP EP10180750.1A patent/EP2286794B8/en not_active Expired - Lifetime
- 2004-10-15 DK DK10180750.1T patent/DK2286794T3/en active
- 2004-10-15 ES ES10180750.1T patent/ES2574231T3/es not_active Expired - Lifetime
- 2004-10-15 EP EP04790494.1A patent/EP1673069B1/en not_active Expired - Lifetime
- 2004-10-15 CA CA2542217A patent/CA2542217C/en not_active Expired - Lifetime
- 2004-10-15 JP JP2006534713A patent/JP5645340B2/ja not_active Expired - Fee Related
- 2004-10-15 PT PT101807501T patent/PT2286794T/pt unknown
- 2004-10-15 WO PCT/EP2004/011655 patent/WO2005039533A1/en not_active Ceased
- 2004-10-15 HU HUE10180750A patent/HUE028648T2/en unknown
- 2004-10-15 US US10/575,779 patent/US20080063699A1/en not_active Abandoned
- 2004-10-15 PL PL10180750.1T patent/PL2286794T3/pl unknown
- 2004-10-15 AU AU2004283464A patent/AU2004283464B8/en not_active Ceased
-
2012
- 2012-07-17 JP JP2012159071A patent/JP2012229255A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004283464B8 (en) | 2011-04-14 |
| EP2286794B8 (en) | 2016-06-01 |
| JP5645340B2 (ja) | 2014-12-24 |
| PT2286794T (pt) | 2016-07-13 |
| EP1673069B1 (en) | 2016-10-12 |
| AU2004283464A1 (en) | 2005-05-06 |
| US20080063699A1 (en) | 2008-03-13 |
| EP2286794A1 (en) | 2011-02-23 |
| CA2542217C (en) | 2018-03-27 |
| AU2004283464B2 (en) | 2011-03-17 |
| JP2012229255A (ja) | 2012-11-22 |
| JP2007508353A (ja) | 2007-04-05 |
| EP1673069A1 (en) | 2006-06-28 |
| CA2542217A1 (en) | 2005-05-06 |
| DK2286794T3 (en) | 2016-07-25 |
| HUE028648T2 (en) | 2016-12-28 |
| EP2286794B1 (en) | 2016-03-30 |
| WO2005039533A1 (en) | 2005-05-06 |
| ES2574231T3 (es) | 2016-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2286794T (pt) | Uso de lipossomas catiónicos contendo placlitaxel | |
| GB0312309D0 (en) | Targeted liposome | |
| IL173478A0 (en) | Form of administration secured against misuse | |
| EP1614386A4 (en) | ECHOGRAPHIC APPARATUS | |
| GB0415345D0 (en) | Alternating voided areas of anti-pads | |
| GB0305150D0 (en) | Use of therapeutic compounds | |
| ZA200407609B (en) | Use of vitamin d compounds | |
| ZA200602386B (en) | 5-Arylpyrimidines as anticancer agents | |
| GB0519079D0 (en) | Asthma preperation | |
| EP1658274A4 (en) | INHIBITORS OF CATHEPSIN S | |
| IL173851A0 (en) | Therapeutic liposomes | |
| GB0327742D0 (en) | Novel uses of known drugs | |
| TWI319322B (en) | Frozen-dried preperation containing prostaglandin | |
| EP1677782A4 (en) | INHIBITORS OF CATHEPSIN S | |
| PL377902A1 (pl) | Nowe zastosowanie kompleksu fosfor-azot-metal | |
| IL172407A0 (en) | Dna-based aptamers for human cathepsin g | |
| GB2399559B (en) | Construction of container | |
| EP1809245A4 (en) | THERAPEUTIC LIPOSOME | |
| GB0326634D0 (en) | Therapeutic agents | |
| PL378419A1 (pl) | Kombinacja leków przeciwcukrzycowych | |
| AU2003261103A8 (en) | Compounds promoting delivery of genes | |
| TW561865U (en) | Improvement of curtain | |
| GB0313027D0 (en) | Mxximus chest protector | |
| SI2108362T1 (sl) | Kationski nosilni sistem, ki vsebuje taksan | |
| GB0307824D0 (en) | Treatment of dyskinesia |